SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches
Clinical Lymphoma Myeloma and Leukemia · 2023-04 · 23 (4) · 238-243
DOI: 10.1016/j.clml.2023.01.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023-04. Verfasst von Caitlin R Rausch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Doxorubicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: ejabbour@mdanderson.org.
Zitieren
APA
Rausch, C. R., Kantarjian, H. M., & Jabbour, E. J. (2023). SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clinical Lymphoma Myeloma and Leukemia, 23(4), 238-243. https://doi.org/10.1016/j.clml.2023.01.013
Vancouver
Rausch CR, Kantarjian HM, Jabbour EJ. SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clinical Lymphoma Myeloma and Leukemia. 2023;23(4):238-243. doi:10.1016/j.clml.2023.01.013
BibTeX
@article{Rausch2023,
author = {Rausch, Caitlin R and Kantarjian, Hagop M and Jabbour, Elias J},
title = {SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
volume = {23},
number = {4},
pages = {238--243},
doi = {10.1016/j.clml.2023.01.013}
}
EUVIMED